gbs ia crm-glycoconjugate vaccine

A monovalent glycoconjugate vaccine candidate designed to prevent infections caused by Group B Streptococcus (GBS) serotype Ia. It consists of the capsular polysaccharide of GBS serotype Ia covalently linked to the CRM197 carrier protein. CRM197 is a non-toxic mutant of diphtheria toxin that enhances the immunogenicity of the polysaccharide by inducing a T-cell dependent immune response. Originally developed by Novartis and later part of the GSK pipeline following the acquisition of Novartis's vaccine division, this vaccine was evaluated in early-phase clinical trials to assess safety and the persistence of functional antibodies in healthy adults, particularly women of childbearing age, to potentially prevent neonatal GBS disease through maternal immunization.

Other names

GBS Ia-CRM197Group B Streptococcus serotype Ia conjugate vaccineGroup B Streptococcus serotype Ia glycoconjugate vaccine